Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Elcubragistat in Healthy Japanese and Caucasian Subjects
NCT05177029Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABX-1431 in post-traumatic stress disorder (PTSD), epilepsy, multiple sclerosis (MS) and 1 more, sponsored by Lundbeck. Primary endpoints: Number of Participants With Adverse Events at Day 26, Area Under the Plasma Concentration-Time Curve From Zero to Infinity and 5 more. Started Nov 2021; status: terminated.
02
Drugs
ABX-1431
03
Conditions
post-traumatic stress disorder (PTSD)epilepsymultiple sclerosis (MS)neurological disorders
Beyond the preview
Go deeper on NCT05177029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177029.